Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd cut its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 14.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,362,683 shares of the company’s stock after selling 5,491,385 shares during the quarter. Teva Pharmaceutical Industries comprises about 5.3% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd’s holdings in Teva Pharmaceutical Industries were worth $543,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after buying an additional 11,334,780 shares in the last quarter. Phoenix Financial Ltd. boosted its holdings in Teva Pharmaceutical Industries by 31.7% in the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after acquiring an additional 9,094,372 shares during the period. Nuveen LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $40,827,000. Assenagon Asset Management S.A. raised its stake in shares of Teva Pharmaceutical Industries by 41.1% during the second quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company’s stock valued at $141,555,000 after purchasing an additional 2,462,064 shares during the period. Finally, Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after purchasing an additional 2,383,500 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.86.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the sale, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $24.86 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $26.38. The firm’s 50-day simple moving average is $20.60 and its 200-day simple moving average is $18.37. The firm has a market cap of $28.51 billion, a PE ratio of -155.38, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the firm earned $0.69 earnings per share. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.